Efficacy and safety of tildrakizumab for the treatment of moderate-to-severe plaque psoriasis of the scalp: A multicenter, randomized, double-blind, placebo-controlled, Phase 3b study supplemental material

Published: 25 March 2024| Version 1 | DOI: 10.17632/zh7bx2my7f.1
Contributors:
Kurt Gebauer, Lynda Spelman, Paul Yamauchi, Jerry Bagel, Tushar Nishandar, Michael Crane, Iris Kopeloff, Mudgal Kothekar, Siu-Long Yao, Howard Sofen

Description

This is the supplemental material for the manuscript titled, "Efficacy and safety of tildrakizumab for the treatment of moderate-to-severe plaque psoriasis of the scalp: A multicenter, randomized, double-blind, placebo-controlled, Phase 3b study" by Gebauer K. et al., 2024.

Files

Categories

Dermatology, Psoriasis

Funding

Sun Pharma

Licence